TNSN99173A1 - Livraison d'agent actif sous forme de poudre seche - Google Patents

Livraison d'agent actif sous forme de poudre seche

Info

Publication number
TNSN99173A1
TNSN99173A1 TNTNSN99173A TNSN99173A TNSN99173A1 TN SN99173 A1 TNSN99173 A1 TN SN99173A1 TN TNSN99173 A TNTNSN99173 A TN TNSN99173A TN SN99173 A TNSN99173 A TN SN99173A TN SN99173 A1 TNSN99173 A1 TN SN99173A1
Authority
TN
Tunisia
Prior art keywords
active agent
dry powder
delivery
lung
hygroscopic
Prior art date
Application number
TNTNSN99173A
Other languages
English (en)
French (fr)
Inventor
Clark Andrew
Kuo Mai-Chang
Lalor Cecily
Original Assignee
Inhale Therapeutic Syst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inhale Therapeutic Syst filed Critical Inhale Therapeutic Syst
Publication of TNSN99173A1 publication Critical patent/TNSN99173A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
TNTNSN99173A 1998-09-14 1999-09-14 Livraison d'agent actif sous forme de poudre seche TNSN99173A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10016398P 1998-09-14 1998-09-14

Publications (1)

Publication Number Publication Date
TNSN99173A1 true TNSN99173A1 (fr) 2005-11-10

Family

ID=22278404

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN99173A TNSN99173A1 (fr) 1998-09-14 1999-09-14 Livraison d'agent actif sous forme de poudre seche

Country Status (44)

Country Link
EP (1) EP1117442A1 (hu)
JP (1) JP2002524535A (hu)
KR (1) KR20010075063A (hu)
CN (1) CN1317977A (hu)
AP (1) AP1374A (hu)
AR (1) AR022090A1 (hu)
AU (1) AU753014B2 (hu)
BG (1) BG105430A (hu)
BR (1) BR9913722A (hu)
CA (1) CA2343920A1 (hu)
CO (1) CO5130023A1 (hu)
CZ (1) CZ2001829A3 (hu)
DZ (1) DZ2892A1 (hu)
EA (1) EA003476B1 (hu)
EE (1) EE200100151A (hu)
GE (1) GEP20043257B (hu)
GT (1) GT199900156A (hu)
HK (1) HK1042231A1 (hu)
HN (1) HN1999000159A (hu)
HR (1) HRP20010189A2 (hu)
HU (1) HUP0103837A3 (hu)
ID (1) ID28845A (hu)
IL (2) IL141562A0 (hu)
IS (1) IS5878A (hu)
LT (1) LT4897B (hu)
LV (1) LV12658B (hu)
MA (1) MA25590A1 (hu)
MY (1) MY129282A (hu)
NO (1) NO20011251L (hu)
NZ (1) NZ510168A (hu)
OA (1) OA11781A (hu)
PA (1) PA8481901A1 (hu)
PE (1) PE20001061A1 (hu)
PL (1) PL195574B1 (hu)
SA (1) SA99200718B1 (hu)
SK (1) SK3442001A3 (hu)
TN (1) TNSN99173A1 (hu)
TR (1) TR200101182T2 (hu)
TW (1) TWI226248B (hu)
UA (1) UA76085C2 (hu)
UY (1) UY25711A1 (hu)
WO (1) WO2000015262A1 (hu)
YU (1) YU24201A (hu)
ZA (1) ZA200101995B (hu)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000075281A2 (en) 1999-06-09 2000-12-14 University Technology Corporation Supercritical fluid-assisted nebulization and bubble drying
US6475468B2 (en) * 2001-02-15 2002-11-05 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
CA2446904A1 (en) * 2001-05-24 2003-04-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
EG24184A (en) * 2001-06-15 2008-10-08 Otsuka Pharma Co Ltd Dry powder inhalation system for transpulmonary
US7759506B2 (en) 2002-02-25 2010-07-20 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
JP2005518453A (ja) 2002-02-25 2005-06-23 ディフュージョン・ファーマシューティカルズ・エルエルシー 二極性トランスカロテノイド塩およびそれらの使用
EP1539246A4 (en) * 2002-07-03 2007-05-16 Brigham & Womens Hospital ADMINISTRATION IN THE CENTRAL AIRWAYS FOR THE SYSTEMIC DELIVERY OF THERAPEUTICS
BR0317392A (pt) * 2002-12-19 2005-12-20 Pharmacia Corp Formulação não-higroscópica incluindo uma droga higroscópica
DE10338403A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverformulierung, enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyrindinyl)-piperazin, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
MXPA06012240A (es) * 2004-04-23 2007-01-31 Cydex Inc Formulacion para inhalador de polvo seco que contiene eter sulfoalquilico-ciclodextrina.
NZ561664A (en) 2005-02-24 2011-02-25 Diffusion Pharmaceuticals Llc Trans carotenoids, their synthesis, formulation and uses
EP1857114A1 (en) * 2005-03-09 2007-11-21 Ono Pharmaceutical Co., Ltd. Particle and preparation containing the particle
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
PT2583668E (pt) 2005-10-26 2015-01-05 Cydex Pharmaceuticals Inc Composições de éter sulfoalquílico de ciclodextrina e métodos para a sua preparação
US20080035143A1 (en) * 2006-08-14 2008-02-14 Sievers Robert E Human-powered dry powder inhaler and dry powder inhaler compositions
CN101541311B (zh) * 2006-10-25 2013-01-23 大日本住友制药株式会社 不易结块的颗粒制剂
EP1925295A1 (de) * 2006-11-22 2008-05-28 Boehringer Ingelheim Pharma GmbH & Co. KG Stabile Pulverformulierung enthaltend ein Anticholinergikum
CN101687757A (zh) 2007-04-13 2010-03-31 扩散药品有限公司 双极性反式类胡萝卜素作为预治疗及其在周围血管疾病的治疗中的应用
BRPI0818119A2 (pt) 2007-10-31 2015-08-04 Diffusion Pharmaceuticals Llc Uma nova classe de produtos terapêuticos que melhoram difusão de molécula pequena
ES2661215T3 (es) 2009-05-20 2018-03-28 Aeras Composiciones víricas; inmunógenas; secadas por pulverización; estables
EP3539542B1 (en) 2009-06-22 2023-04-19 Diffusion Pharmaceuticals LLC Diffusion enhancing compounds and their use with a thrombolytic
AU2011262361A1 (en) 2010-06-02 2013-01-10 Diffusion Pharmaceuticals Llc Oral formulations of bipolar trans carotenoids
BR112014026957A8 (pt) * 2012-05-03 2018-01-16 Janssen R&D Ireland micropartícula, composição compreendendo a mesma, seu uso e sistema de distribuição nasal relacionados ao tratamento de infecções do trato respiratório superior
BR112015010601B1 (pt) * 2012-11-09 2022-07-19 Civitas Therapeutics, Inc. Composição farmacêutica e uso da composição
WO2015042352A1 (en) * 2013-09-20 2015-03-26 Virginia Commonwealth University Delivery of particles using hygroscopic excipients
AU2015338717B2 (en) 2014-10-31 2018-12-20 Glaxosmithkline Intellectual Property Development Limited Powder formulation
JP7032320B2 (ja) 2016-03-24 2022-03-08 ディフュージョン・ファーマシューティカルズ・エルエルシー 癌を処置するための、化学療法及び放射線療法を伴う二極性トランスカロテノイドの使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3155573A (en) * 1958-05-06 1964-11-03 Benger Lab Ltd Inhalant composition and method of making same
ATE222754T1 (de) * 1992-06-12 2002-09-15 Teijin Ltd Ultrafeines pulver zur inhalation und dessen herstellung
US6524557B1 (en) * 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
ATE287257T1 (de) * 1997-01-16 2005-02-15 Massachusetts Inst Technology Zubereitung von partikelhaltigen arzneimitteln zur inhalation
US6086376A (en) * 1998-01-30 2000-07-11 Rtp Pharma Inc. Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant

Also Published As

Publication number Publication date
AU753014B2 (en) 2002-10-03
KR20010075063A (ko) 2001-08-09
BR9913722A (pt) 2001-05-29
NO20011251L (no) 2001-04-17
HRP20010189A2 (en) 2005-04-30
PL346768A1 (en) 2002-02-25
GT199900156A (es) 2001-03-07
AR022090A1 (es) 2002-09-04
CO5130023A1 (es) 2002-02-27
LT2001021A (en) 2001-11-26
OA11781A (en) 2005-07-26
DZ2892A1 (fr) 2003-12-15
EP1117442A1 (en) 2001-07-25
HUP0103837A3 (en) 2002-11-28
WO2000015262A1 (en) 2000-03-23
HK1042231A1 (zh) 2002-08-09
PA8481901A1 (es) 2002-04-25
MA25590A1 (fr) 2002-12-31
EA003476B1 (ru) 2003-06-26
NO20011251D0 (no) 2001-03-13
LV12658A (lv) 2001-05-20
CZ2001829A3 (cs) 2001-09-12
YU24201A (sh) 2003-08-29
JP2002524535A (ja) 2002-08-06
TWI226248B (en) 2005-01-11
ZA200101995B (en) 2002-03-11
NZ510168A (en) 2003-09-26
IL141562A0 (en) 2002-03-10
IL141562A (en) 2007-07-24
BG105430A (en) 2001-12-29
SK3442001A3 (en) 2001-11-06
ID28845A (id) 2001-07-05
AP2001002093A0 (en) 2001-03-31
UA76085C2 (en) 2006-07-17
PL195574B1 (pl) 2007-10-31
LT4897B (lt) 2002-02-25
EE200100151A (et) 2002-06-17
HUP0103837A2 (hu) 2002-05-29
SA99200718B1 (ar) 2006-11-04
LV12658B (lv) 2001-09-20
CA2343920A1 (en) 2000-03-23
AU6039799A (en) 2000-04-03
MY129282A (en) 2007-03-30
AP1374A (en) 2005-02-28
GEP20043257B (en) 2004-06-25
UY25711A1 (es) 1999-11-17
CN1317977A (zh) 2001-10-17
EA200100300A1 (ru) 2001-10-22
TR200101182T2 (tr) 2001-09-21
HN1999000159A (es) 1999-11-11
IS5878A (is) 2001-03-05
PE20001061A1 (es) 2000-10-08

Similar Documents

Publication Publication Date Title
TNSN99173A1 (fr) Livraison d'agent actif sous forme de poudre seche
TNSN99188A1 (fr) Livraison d'agent actif atomise par modulation resistance de debit
Haberman et al. Contact dermatitis from beryllium in dental alloys
HUP0004924A2 (hu) Ciklodextrineket tartalmazó gyógyászati készítmények
TNSN99038A1 (fr) Livraison d'un agent actif atomise
Sas et al. The intra-oral distribution of unstimulated and chewing-gum-stimulated parotid saliva
DE60326887D1 (de) Pharmazeutische zusammensetzungen enthaltend botulinumtoxin und humanes serum-albumin
ATE232382T1 (de) Pharmazeutische zusammensetzungen mit schneller freisetzung von wirkstoffen
CA2038097A1 (en) Method and composition for coiontophoresis
WO2001041707A3 (en) Modulation of in vivo glutamine and glycine levels in the treatment of autism
ATE264102T1 (de) Nicotin enthaltende pharmazeutische zusammensetzungen mit schneller transmukosaler absorption
MX9605940A (es) Compuestos bioaromaticos que llevan un grupo adamantilo en orto, composiciones farmaceuticas y cosmeticas que los contienen y utilizaciones.
BR9906920A (pt) "tts contendo um antioxidante"
WO2008013929A3 (en) Anti-migraine oral spray formulations and methods
BR0308137A (pt) Formulações de droga de liberação constante contendo um peptìdeo veìculo
Somasundaram et al. In vitro absorption of [14C] leucine during inflammation and the effect of antiinflammatory drugs in the jejunum of rats
Oz et al. A model for chronic mucosal inflammation in IBD and periodontitis
EE04038B1 (et) Inhaleeritav formoterooli sisaldav ravimvorm puistetihedusega 0,28 kuni 0,38 g/ml, meetod selle valmistamiseks ning kasutamine
TR200201262T2 (tr) Çiklet bileşimleri.
JP2004513093A5 (hu)
BRPI9910024B8 (pt) uso de uma mistura de alcoóis de açúcar contendo 6-o-alfa-d-glicopiranosil-d-sorbitol (1,6-gps) e 1-o-alfa-d-glicopiranosil-d-manitol (1,1-gpm) in vitro, e composição farmacêutica para consumo humano ou animal
AU9363398A (en) Hepatitis c receptor protein cd81
Purushotham et al. Absorption of epidermal growth factor occurs through the gastrointestinal tract and oral cavity in adult rats
DE69513767D1 (de) Pharmazeutische Zusammensetzung in Form eines Gels mit Chondroitinsulfat in Salzform zur oralen Verabreichung
JPS5940137B2 (ja) 経口投与用医薬組成物